orfiril retard forðatafla 300 mg
desitin arzneimittel gmbh - natrii valproas - forðatafla - 300 mg
plasmalyte innrennslislyf, lausn
baxter medical ab* - sodium chloride; kalii chloridum; magnesii chloridum; sodium acetate trihydrate; natrii gluconas - innrennslislyf, lausn
picoprep mixtúruduft, lausn
ferring lægemidler a/s - natrii picosulfas inn; magnesii oxidum; citric acid - mixtúruduft, lausn
natriumklorid fresenius kabi leysir fyrir stungulyf 9 mg/ml
fresenius kabi ab - natrii chloridum - leysir fyrir stungulyf - 9 mg/ml
fucidin smyrsli 20 mg/g
leo pharma a/s* - natrii fusidas nfn - smyrsli - 20 mg/g
natriumklorid b. braun (natriumklorid braun) innrennslislyf, lausn 9 mg/ml
b.braun melsungen ag* - natrii chloridum - innrennslislyf, lausn - 9 mg/ml
natriumklorid b. braun leysir fyrir stungulyf 9 mg/ml
b.braun melsungen ag* - natrii chloridum - leysir fyrir stungulyf - 9 mg/ml
selevitan, vet. stungulyf, lausn
boehringer ingelheim animal health nordics a/s - natrii selenis; tocopherolum (alfa) acetat - stungulyf, lausn
laxoberal dropar til inntöku, lausn 7,5 mg/ml
opella healthcare france s.a.s. - natrii picosulfas inn - dropar til inntöku, lausn - 7,5 mg/ml
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - umboðsmenn fyrir húðbólgu, að undanskildu barkstera - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.